TR200102273T2 - GNRH-II ihtiva eden kontrollü salınış formülasyonu. - Google Patents

GNRH-II ihtiva eden kontrollü salınış formülasyonu.

Info

Publication number
TR200102273T2
TR200102273T2 TR2001/02273T TR200102273T TR200102273T2 TR 200102273 T2 TR200102273 T2 TR 200102273T2 TR 2001/02273 T TR2001/02273 T TR 2001/02273T TR 200102273 T TR200102273 T TR 200102273T TR 200102273 T2 TR200102273 T2 TR 200102273T2
Authority
TR
Turkey
Prior art keywords
controlled release
release formulation
formulation containing
xaa1
xaa3
Prior art date
Application number
TR2001/02273T
Other languages
English (en)
Inventor
Qi Steve
Akinsanya Karen
Hayward Amanda
Original Assignee
Ferring B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring B.V. filed Critical Ferring B.V.
Publication of TR200102273T2 publication Critical patent/TR200102273T2/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Bir terapötik peptidin veya tuzunun kontrollü salinisi için bir farmasötik formülasyon; bu peptit asagidaki diziyi haizdir: pyroGlu-His-Trp-Ser-Xaa1-Gly-Xaa2-Xaa3-Pro-Gly-NH2; bu dizide: Xaa1 His veya Tyr'dir; Xaa2 Trp veya Leu'dur; ve Xaa3 Tyr veya Arg'dir. Burada sart Xaa1 Tyr ve Xaa2 Leu oldugunda Xaa3 Arg degildir. Bu formülasyon ayrica farmasötik olarak kabul edilebilir, biyolojik olarak parçalanabilir bir polimer ihtiva eder.
TR2001/02273T 1998-12-03 1999-12-02 GNRH-II ihtiva eden kontrollü salınış formülasyonu. TR200102273T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9826662A GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation

Publications (1)

Publication Number Publication Date
TR200102273T2 true TR200102273T2 (tr) 2001-12-21

Family

ID=10843631

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02273T TR200102273T2 (tr) 1998-12-03 1999-12-02 GNRH-II ihtiva eden kontrollü salınış formülasyonu.

Country Status (22)

Country Link
EP (1) EP1140133A1 (tr)
JP (1) JP2002531411A (tr)
KR (1) KR20010089538A (tr)
CN (1) CN1332635A (tr)
AU (1) AU770676B2 (tr)
BR (1) BR9915943A (tr)
CA (1) CA2353798A1 (tr)
CZ (1) CZ20011893A3 (tr)
EE (1) EE200100293A (tr)
GB (1) GB2344287A (tr)
HR (1) HRP20010421A2 (tr)
HU (1) HUP0104943A3 (tr)
IL (1) IL143496A0 (tr)
MX (1) MXPA01005543A (tr)
NO (1) NO20012636L (tr)
NZ (1) NZ511984A (tr)
PL (1) PL348575A1 (tr)
RU (1) RU2233170C2 (tr)
SK (1) SK7552001A3 (tr)
TR (1) TR200102273T2 (tr)
WO (1) WO2000032218A1 (tr)
ZA (1) ZA200104530B (tr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1909814B1 (en) * 2005-07-26 2015-06-24 Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) Peptides for induction and enhancement of apoptosis in tumor cells
GB0616111D0 (en) 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
CN102448482A (zh) 2009-03-27 2012-05-09 范安德尔研究所 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法
WO2011032099A1 (en) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Methods of treating diastolic dysfunction and related conditions
WO2011056572A1 (en) 2009-10-27 2011-05-12 The Board Of Trustees Of The University Of Illinois Methods of diagnosing diastolic dysfunction
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
DK2547359T3 (en) 2010-03-15 2016-06-06 The Board Of Trustees Of The Univ Of Illionis Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
US8940860B2 (en) 2010-06-16 2015-01-27 Indiana University Research And Technology Corporation Single-chain insulin agonists exhibiting high activity at the insulin receptor
US20120004182A1 (en) 2010-07-02 2012-01-05 Carsten Gruendker Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
EP2655401B1 (en) 2010-12-20 2016-03-09 The Regents of the University of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
ES2713952T3 (es) 2010-12-22 2019-05-24 Univ Indiana Res & Tech Corp Análogos de glucagón que muestran actividad de receptor de GIP
RS56173B1 (sr) 2011-06-22 2017-11-30 Univ Indiana Res & Tech Corp Koagonisti receptora za glukagon/glp-1 receptora
WO2013055791A1 (en) 2011-10-10 2013-04-18 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
CN103957927B (zh) 2011-11-17 2016-11-09 印第安纳大学研究及科技有限公司 呈现糖皮质激素受体活性的胰高血糖素超家族肽
US9573987B2 (en) 2011-12-20 2017-02-21 Indiana University Research And Technology Corporation CTP-based insulin analogs for treatment of diabetes
WO2013188740A1 (en) 2012-06-14 2013-12-19 Ambrx, Inc. Anti-psma antibodies conjugated to nuclear receptor ligand polypeptides
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
WO2013192130A1 (en) 2012-06-21 2013-12-27 Indiana University Research And Technology Corporation Analogs of glucagon exhibiting gip receptor activity
AU2013323669B2 (en) 2012-09-26 2018-03-01 Indiana University Research And Technology Corporation Insulin analog dimers
AU2014241743B2 (en) 2013-03-14 2018-07-05 Indiana University Research And Technology Corporation Insulin-incretin conjugates
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
US10232020B2 (en) 2014-09-24 2019-03-19 Indiana University Research And Technology Corporation Incretin-insulin conjugates
EP3250609A4 (en) 2015-01-26 2018-07-11 The University of Chicago Il13ra alpha 2 binding agents and use thereof in cancer treatment
CN107835820B (zh) 2015-01-26 2021-10-15 芝加哥大学 识别癌症特异性IL13Rα2的CAR T细胞
CN104789524A (zh) * 2015-04-30 2015-07-22 四川大学 骨质疏松大鼠原代成骨细胞分离培养方法及应用
US20180201937A1 (en) 2015-08-04 2018-07-19 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
JP2020505379A (ja) * 2017-01-20 2020-02-20 イミューン システム レギュレェイション ホールディング エービー 新規化合物（イムノレリン）
WO2019006235A1 (en) 2017-06-30 2019-01-03 Amgen Inc. METHODS OF TREATING CARDIAC INSUFFICIENCY WITH CARDIAC SARCOMER ACTIVATORS
WO2019028316A1 (en) 2017-08-03 2019-02-07 Amgen Inc. INTERLEUKIN-21 MUTÉINS AND METHODS OF TREATMENT
AR112797A1 (es) 2017-09-08 2019-12-11 Amgen Inc Inhibidores de kras g12c y métodos para utilizarlos
KR20200070238A (ko) 2017-09-18 2020-06-17 더 리전트 오브 더 유니버시티 오브 캘리포니아 클라우딘6 항체 및 암치료방법
MX2020007291A (es) 2018-01-12 2020-09-10 Amgen Inc Anticuerpos anti-pd-1 y metodos de tratamiento.
WO2020055913A1 (en) 2018-09-10 2020-03-19 Cardax, Inc. Methods of reducing- c-reactive protein and/or treating cardiovascular disease
WO2020191344A1 (en) 2019-03-20 2020-09-24 The Regents Of The University Of California Claudin-6 bispecific antibodies
AU2020241896A1 (en) 2019-03-20 2021-09-23 The Regents Of The University Of California Claudin-6 antibodies and drug conjugates
EP3785734B1 (en) 2019-03-26 2023-04-12 Novel Pharma Inc. Long-acting fatty acid-binding gnrh derivative and pharmaceutical composition comprising same
CA3136496A1 (en) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Drug adsorbed highly porous activated carbon for enhanced drug delivery
WO2020223177A1 (en) 2019-04-29 2020-11-05 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
US20220195059A1 (en) 2019-04-30 2022-06-23 Instituto de Medicina Molecular João Lobo Antunes Rank Pathway Inhibitors in Combination with CDK Inhibitors
CA3140904A1 (en) 2019-06-24 2020-12-30 Amgen Inc. Inhibition of sirp-gamma for cancer treatment
WO2021042048A1 (en) 2019-08-30 2021-03-04 Research Institute At Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associated with mitochondrial dysfunction
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
WO2022159575A1 (en) 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
WO2023137161A1 (en) 2022-01-14 2023-07-20 Amgen Inc. Triple blockade of tigit, cd112r, and pd-l1
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
DE3414595A1 (de) * 1984-04-18 1985-10-31 Hoechst Ag, 6230 Frankfurt Verwendung von gonadoliberin und gonadoliberinagonisten zur behandlung klimakterischer beschwerden
US4540513A (en) * 1984-09-25 1985-09-10 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Decapeptide having gonadotropin releasing activity
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
CA2192773C (en) * 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
AU3388597A (en) * 1996-06-13 1998-01-07 University Of Cape Town Human type ii gonadotropin-releasing hormone receptor

Also Published As

Publication number Publication date
PL348575A1 (en) 2002-06-03
MXPA01005543A (es) 2003-07-14
IL143496A0 (en) 2002-04-21
NO20012636D0 (no) 2001-05-29
ZA200104530B (en) 2002-06-04
EP1140133A1 (en) 2001-10-10
BR9915943A (pt) 2001-08-21
JP2002531411A (ja) 2002-09-24
NZ511984A (en) 2002-11-26
GB9826662D0 (en) 1999-01-27
NO20012636L (no) 2001-07-12
CN1332635A (zh) 2002-01-23
AU1573200A (en) 2000-06-19
GB2344287A (en) 2000-06-07
KR20010089538A (ko) 2001-10-06
EE200100293A (et) 2002-08-15
AU770676B2 (en) 2004-02-26
WO2000032218A1 (en) 2000-06-08
SK7552001A3 (en) 2002-02-05
CZ20011893A3 (cs) 2002-05-15
HUP0104943A2 (en) 2002-06-29
RU2233170C2 (ru) 2004-07-27
CA2353798A1 (en) 2000-06-08
HUP0104943A3 (en) 2002-08-28
HRP20010421A2 (en) 2002-06-30

Similar Documents

Publication Publication Date Title
TR200102273T2 (tr) GNRH-II ihtiva eden kontrollü salınış formülasyonu.
MX9603858A (es) Copolimeros de bloque y de injerto y metodos relacionados con los mismos.
KR890013060A (ko) Lhrh 길항제로서 유용한 lhrh의 노나펩타이드 및 데카펩타이드 동족체
BG102022A (en) Metering inhaler for salmetrol
EP1077070A3 (en) Oral drug delivery compositions
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
DE60231731D1 (de) Vorrichtung zur nasalen oder oralen verabreichung eines medikamentes
WO2003079972A3 (en) Active agent delivery systems and methods for protecting and administering active agents
DK1061900T4 (da) Dermale præparater
ES2126536B1 (es) "preparado farmaceutico para administracion intranasal y procedimientopara su produccion".
GT199900151A (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial.
BR9714015A (pt) Formulações farmacêuticas para distribuição de droga prolongada
BR0309544A (pt) Preparação farmacêutica contendo oxicodona e naloxona
EP0818991A4 (en) EXCIPIENT FOR INSUFFLATION, GRADUALLY RELEASED, FOR MEDICINES
EP0993831A3 (en) Compounds and compositions for delivering active agents
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
ATE338771T1 (de) Antagonisten des intestinotrophen glp-2 peptides
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
DE69727956D1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
MX2010002018A (es) Peptido de cdh3 y agente medicinal que comprende al mismo.
PT885014E (pt) Composicoes farmaceuticas contendo polimeros orto ester tamponados
AU7134898A (en) Biodegradable microparticles for the sustained delivery of therapeutic drugs
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
AU7723700A (en) Non-mammalian gnrh analogs and uses thereof in regulation of fertility and pregnancy
TR199900596T2 (tr) Otoimün hastaliklara karsi maddeler olarak proteinlerin kullanimi.